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We studied the effect of a novel purine acyclic nucleoside, 9-(1,3-dihydroxy-2-
propoxymethyl)guanine (DHPG), on human cytomegalovirus (HCMV) replica-
tion. The susceptibility of HCMV to this drug was monitored in cell culture by
plaque reduction assay. HCMV replication of various strains was inhibited to the
extent of 50%o by 1 to 5 ,uM DHPG. DHPG was highly specific in its anti-HCMV
activity, since at concentrations as high as 100 ,uM it did not exert any detectable
inhibitory effect on uninfected cell macromolecular synthesis and cell growth. At
concentrations of 2 to 4 ,uM, the drug inhibited the synthesis of six virus-specific
polypeptides with molecular weights of 200,000 (VP200), 150,000 (VP150), 67,000
(VP67), 54,000 (VP54), 32,000 (VP32), and 27,000 (VP27) up to 96 h after
infection. HCMV DNA synthesis was also considerably suppressed at concentra-
tions of 2 to 4 ,M DHPG. Upon removal of the inhibitor, however, viral DNA
synthesis resumed and infectious virus reappeared, indicating that this inhibition
was a virostatic reversible-type inhibition.
Ideal antiviral chemotherapy should be specif-
ic for the inhibition of viral replication with
minimum toxicity to the host. Of the existing
antiviral compounds, acyclovir (ACV) was dis-
covered to be a potent and selective inhibitor of
herpes simplex virus types 1 (HSV-1) and 2
(HSV-2), with little effect on uninfected cells (5).
A virus-encoded thymidine kinase (TK) is re-
quired to activate ACV in infected cells (5).
ACV has been found to have limited anti-human
cytomegalovirus (HCMV) activity (4, 11, 13)
since HCMV does not encode virus-specific TK
enzyme in infected cells (6, 16).
Recently, four companies (Syntex Inc., Biolo-
gics Co., Wellcome Research Laboratories, and
Merck Sharpe and Dohme Research Labora-
tories) have independently developed a novel
guanosine analog, 9-(1,3-dihydroxy-2-propoxy-
methyl)guanine (DHPG). Besides its extreme
potency against HSV-1 and HSV-2 (1, 3, 12, 14,
15), DHPG has been demonstrated to effectively
inhibit HCMV replication in vitro (14). In this
communication, we report the in vitro anti-
HCMV activity ofDHPG and its mode of action
on viral DNA replication and virus-specific pro-
tein synthesis. Our results confirm and extend
the observations made by other investigators
(14).
MATERIALS AND METHODS
Chemicals and radlochemicals. DHPG was synthe-
sized and provided by Syntex Inc., Palo Alto, Calif.
3H-labeled amino acids and [5-3H]UTP were pur-
chased from New England Nuclear, Boston, Mass.
Cells and virus. Human fibroblastic diploid cells,
WI-38 strain, were obtained from the American Type
Culture Collection, Rockville, Md. Cells at passages
20 to 26 were used. HCMV strains Clegg and TW087
(isolated from semen and cervix, respectively, by E.-
S. Huang), strain Towne (isolated from a congenitally
infected baby), strain BT1493 (isolated from an organ
transplant), and strain Major (isolated from a prostate)
were used in this study. Strains Towne and BT1493
were provided by S. A. Plotkin, and strain Major was
provided by F. Rapp.
Synthesis of 3H-labeled RNA to HCMV strain Towne
DNA. The virus obtained from extracellular fluids was
purified by two cycles of ultracentrifugation in sucrose
and CsCl gradients, as described elsewhere (9). The
purified virus was then subjected to pronase digestion
and phenol extraction. Viral DNA which banded in the
CsC1 equilibrium gradient at a density of 1.716 g/cm3
was used for the preparation of [3H]cRNA, with
[3H]UTP as the radiolabeled substrate, according to
the procedure of Huang (8).
c-RNA-DNA membrane hybridization. Using slightly
modified versions of the procedures of Gillespie and
Spiegelman (7) and Huang (8), we determined the
effect of DHPG on viral DNA synthesis. Briefly,
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Towne virus-infected and mock-infected WI-38 cells
were lysed with 10 mM Tris-hydrochloride (pH 8.0-
10mM EDTA-1% sodium dodecyl sulfate and then
digested with pronase (1 mg/m,l) for 3 h at 37°C. The
mixture was extracted with phenol and precipitated
with alcohol. To remove RNA, the obtained nucleic
acid was incubated for 3 h at 37°C with heat-pretreated
pancreatic RNase A (40 Fg/ml) in 10 mM Tris-hydro-
chloride (pH 7.4)-i mM EDTA. After further purifica-
tion by one more cycle of phenol extraction and
alcohol precipitation, the DNA was dissolved in 1 x
SSC (SSC = 0.15 M NaCl and 0.015 M sodium citrate).
For [3H]cRNA-DNA membrane hybridization, the in-
fected or mock-infected cell DNA was first denatured
in 0.5 N NaOH for 2 h at 37°C and then neutralized to a
final pH of 7.4 with 1.1 N HCI in 0.2 M Tris. The
mixture was then adjusted to 6x SSC, and single-
stranded DNA was immobilized onto a nitrocellulose
filter. After vacuum drying at 80°C for 2 h, the DNA-
immobilized filters were prehybridized at 66°C for 1 h
in buffer A (6x SSC, Q.1% sodium dodecyl sulfate, and
1 mg of yeast tRNA per ml). Then HCMV [3H]cRNA
at 200,000 cpm (specific activity, 1.2 x 107 cpm/,ug) in
buffer A was applied to each filter in glass scintillation
vials. The hybridization was performed at 66°C for 18
h. After thorough washing with 2x SSC, the nitrocel-
lulose filters were treated with RNase A to remove any
unhybridized RNA. After the filters were dried, radio-
activity was determined with a liquid scintillation
counter.
Effect of DHPG on viral protein synthesis in poly-
acrylamide gel electrophoresis. WI-38 monolayers were
mock or virus infected (multiplicity of infection, 1 to
2). After adsorption for 2 h the virus inoculum was
replaced with minimum essential medium supplement-
ed with 4% fetal calf serum and various concentrations
of DHPG. At various times after infection, the culture
cells were pulse-labeled for 2 h with [3H]-labeled
amino acids (5 pCi/ml) in minimum essential medium
containing 1/20 the strength of regular amino acids.
The cells were sonicated postinfection in buffer B (10
mM Tris-hydrochloride, pH 8.0, 10 mM j-mercap-
toethanol and 1 mM p-methylphenylsulfonyl fluoride),
and the labeled proteins were precipitated with 10%
trichloroacetic acid. After being washed once each
with ethanol and acetone, the proteins were electro-
phoresed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis through 9%o acrylamide gels in a
Tris buffer system as described by Laemmli (10). After
the gels were subjected to fluorography (2), autoradi-
ography was done by exposing the dried gel to X-ray
film at -70°C for 7 days.
Plaque formation assay. The plaque formation assay
was used to determine the antiviral activity of DHPG.
Confluent WI-38 cells in six-well cluster plates were
incubated with 200 PFU of virus in 0.2 ml of minimum
essential medium-4% fetal calf serum. After incuba-
tion, the nonadsorbed virus was removed and the
cultures were overlaid with 1% agarose in minimum
essential medium-4% fetal calf serum and appropriate
concentrations of DHPG. Four days later, a second
agarose layer was added. On day 9 postinfection, the
monolayers were fixed (with phosphate-buffered 10%
Formalin), stained (with 0.03% crystal violet), and
scored for plaques. Then the concentration needed to
reduce plaque formation by 50%o (ID50) was calculated
by counting the number of plaques in the control wells
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and comparing them with the surviving plaques in the
presence of various concentrations of DHPG. We also
used this assay to examine the release of infectious
virus from drug-treated and post-drug-treated infected
cell cultures.
RESULTS
Effect of DHPG on HCMV replication in cell
cultures. The antiviral activity of DHPG was
measured by plaque reduction assay and ex-
pressed in terms of ID50, which was defined as
the concentration of DHPG at which viral repli-
cation was inhibited by 50%. The results are
summarized in Table 1. DHPG exhibited a po-
tent anti-HCMV activity and had ID50s ranging
from 1 to 4.8 ,uM for five HCMV isolates tested.
Effect of DHPG on HCMV DNA synthesis in
virus-infeciedWI-38 cells. The amount of viral
DNA synthesis in virus-infected cells was moni-
tored by nucleic acid hybridization with virus-
specific [3H]cRNA as a probe. HCMV DNA
synthesis was initiated approximately 20 h after
infection and increased exponentially for up to
96 h (Fig. 1). In the presence of 2 or 4 ,um
DHPG, viral DNA synthesis was suppressed
substantially compared with'that of nontreated
infected cells (Fig. 1). However, upon removal
of the drug, viral DNA synthesis resumed (Fig.
1).
Comparison of protein synthesis in sodium do-
decyl sulfate-polyacrylamide gel electrophoresis
between DHPG-treated and nontreated infected
cell systems. The toxicity of DHPG for uninfect-
ed cells was monitored for 24 h (48 h after
treatment) by measuring the inhibition of incor-
poration of 3H-labeled amino acids into proteins
and [3H]thymidine into DNA. At a concentra-
tion of 100 ,uM DHPG, no significant inhibition
was detected. Incorporation of radiochemicals
into cell macromolecules was inhibited by 50%
at 300 ,uM DHPG (ID50). On the other hand, the
synthesis of virus-specific proteins was inhibited
at drug concentrations of 2 to 4 ,uM, which were
well below the cytotoxic level (ID50 = 300 JIM).
Figure 2 shows the inhibition of six virus-specif-
ic polypeptides (VP200, VP150, VP67, VP54,
VP32, and VP27) by the drug for up to 96 h after
infection. However, the expression of VP67 was
not completely inhibited. These proteins were
detected in non-drug-treated infected cells 48 h
TABLE 1. Antiviral activity of DHPG on HCMV
replication
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FIG. 1. Effect of DHPG on HCMV strain Towne
DNA replication in virus-infected WI-38 cells. The
drug was added to the virus-infected cell cultures at a
final concentration of 2 or 4 FM immediately after
virus adsorption. At various times after infection,
DNA was extracted from the infected cells for virus
genome quantitation by [3H]cRNA-DNA membrane
hybridization. Amounts of DNA and HCMV-specific
[3H]cRNA applied to each filter were 20 ,g and 4 x
10' cpm, respectively. The nucleic acid hybridization
was performed as described previously (8). Symbols:
0, viral DNA content of cultures without drug treat-
ment; A-A and U-U, viral DNA content in the
presence of 2 and 4 FM DHPG, respectively; A---A
and _-U, recovery of DNA synthesis after removal
of 2 and 4 AM DHPG.
after infection. Thus, these polypeptides should
be virus-specific late antigens.
DISCUSSION
A recently developed ACV congener, DHPG,
was demonstrated to be an extremely potent
antiherpetic compound with low toxicity to nor-
mal cells (3, 12, 14, 15). The modes of action of
DHPG and ACV are similar in that the herpes
TK specifically phosphorylates each nucleoside
and both compounds selectively inhibit viral
replication over cell proliferation (1, 3, 5, 12, 14,
15). It has been observed that ACV and DHPG
are totally inactive against HSV mutants which
do not induce virus TK in infected cells (3, 5, 14,
15), indicating that a herpes-encoded TK en-
zyme is required to activate DHPG as well as
ACV in infected cells.
Recently, DHPG was reported to have a mar-
ginal activity against Epstein-Barr virus (ID50 =
32 p.M) and to have no activity against HCMV
even at a concentration as high as 390 ,uM (15).
In contrast, Smee and colleagues (14) demon-
strated that, besides its potency against HSV-1
and HSV-2, DHPG effectively inhibited a strain
ofHCMV (AD169) by 50o at 7 AM. In addition,
at concentrations as low as 0.05 ,uM, DHPG re-
duced Epstein-Barr virus genome numbers in
P3HR-1 cells by 50% (J. S. Pagano, J. W. Six-
bey, and J.-C. Lin, J. Antimicrob. Chemother.,
in press; J.-C. Lin, M. C. Smith, and J. S.
Pagano, submitted for publication). In the pre-
sent investigation, we also demonstrate that
DHPG is a potent and selective anti-HCMV
agent with viral ID50s ranging from 1 to 5 ,uM,
depending upon the virus strain used (Table 1).
The ID50 for cell growth was 300 ,uM. Our data
are in reasonable agreement with the data re-
ported by Smee and co-workers (14). The dis-
crepancy between positive and negative results
of anti-Epstein-Barr virus and anti-CMV activi-
ties of DHPG as reported by others may be due
to the use of different methodologies. Smith et
al. (15) examined the effect of DHPG on the
expression of virus-specific antigens which were
expressed despite the inhibition of viral DNA
synthesis, whereas in this study and in the
FIG. 2. Time-course synthesis of virus-specific
proteins in HCMV-infected WI-38 cells. Protein syn-
thesis was studied by incorporation of 3H-labeled
amino acids (5 tjCi/ml) at various times after infection.
The polyacrylamide gel was subjected to fluorography
and autoradiography by exposing the dried gel to X-
ray film at -70°C for 7 days. Numbers in column MW
indicate molecular weight x 103. M = mock infected.
Arrows indicate inhibition of the virus-specific pro-
teins by DHPG at the designated concentration.
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studies of Smee et al. (14), Pagano et al. (in
press), and Lin et al. (submitted) the inhibition
of HCMV and Epstein-Barr virus replication
was determined by the inhibition of viral DNA
and virus-specific protein syntheses and the
reduction of virus progeny yield.
Quantitation of viral DNA synthesis, using
cRNA-DNA hybridization, demonstrated a dra-
matic inhibition ofHCMV DNA replication at 2
to 4 ,M DHPG (Fig. 1). At these drug concen-
trations, the synthesis of five virus-specific late
polypeptides (VP200, VP150, VP54, VP32, and
VP27) was markedly inhibited (Fig. 2). The
additional virus-specific polypeptide (VP67)
which was inhibited substantially at an early
stage of infection accumulated to a certain ex-
tent at a late stage of infection (Fig. 2). The
resumption of VP67 (Fig. 2) and a gradual and
low-level increase in the concentration of viral
DNA sequences (Fig. 1) at a later stage of drug
treatment may be due to degradation of the drug
in cell cultures. After removal of the inhibitor
from cell cultures, viral DNA synthesis resumed
(Fig. 1) and infectious virus became detectable.
These phenomena suggest that the inhibitory
effect by DHPG of HCMV replication was a
virostatic reversible type of inhibition.
In spite of the structural resemblance of
DHPG to ACV, the therapeutic index of DHPG
against HCMV is much higher in cell culture
than that of ACV. The broader antiviral spec-
trum, greater inhibitory effect, lower cytotoxic-
ity, and higher solubility of DHPG (14, 15)
compared with other existing antiherpetic com-
pounds make DHPG a potential candidate for
antiherpes chemotherapy.
The ineffectiveness ofDHPG on TK- mutants
of HSV-1 and HSV-2 (3, 14, 15) suggests the
importance of the virus-encoded TK enzyme in
the molecular action of this drug. Since HCMV
does not encode a virus-specific TK, the mecha-
nism by which DHPG exhibits the inhibitory
effect against HCMV in vitro is still unclear. It is
one of our mijor interests to study the possible
role of virus-stimulated cellular TK enzyme (6,
16) in regard to the anti-HCMV activity of
DHPG.
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